Customize
Quick Links

Accreditation/
Credit Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource®, LLC and Pharmacy Times Continuing Education. Physicians’ Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.

This activity is approved for AMA PRA Category 1 Credit™.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669.


Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is eligible for ACPE credit; see final CPE activity announcement for specific details.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
Physicians’ Education Resource ®, LLC.
All rights reserved.

36th Annual CFS®

36th Annual CFS®


36th Annual CFS®

Wednesday, November 7, 2018 – Friday, November 9, 2018
New York Marriott Marquis
1535 Broadway

New York, NY 10036
(800) 843-4898

Overview:

Rapid changes continue to occur in the management of solid and hematologic malignancies. Just this past year, practice-changing diagnostic, therapeutic, and supportive care strategies have entered clinical practice, and many more are poised to enter the field. Improved outcomes are achievable across multiple lines of care with the application of optimized testing approaches, locoregional and systemic therapies, targeted therapies, immunotherapies, and multimodal strategies. Critical knowledge and competence gaps among practitioners must be addressed to ensure that these approaches are effectively and safely integrated into practice. Each year, the Chemotherapy Foundation Symposium® (CFS®), brings together more than 2000 healthcare professionals for 3 days, with the aim of promoting the delivery of evidence-based, state-of-the-art cancer care for routine and the most challenging clinical scenarios. At the 36th Annual CFS®, our internationally renowned faculty will provide expert insights on the latest developments in cancer therapeutics, offering oncology practitioners an unparalleled opportunity to learn how innovative approaches fit into existing treatment paradigms to optimize care and outcomes for their patients with cancer.
 

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Boehringer Ingeheim Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Eisai, Inc., Ignyta, Incyte Corporation, Ipsen Biopharmaceuticals, Inc., Lilly, Novartis Pharmaceuticals Corporation, Novocure, Pharmacyclics LLC, an AbbVie Company, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, Taiho Oncology, and Takeda Oncology.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Target Audience:

This educational activity is directed toward oncologists, hematologists, nurses, nurse practitioners, and pharmacists interested in the treatment/management of patients with cancer. Radiotherapists, immunologists, fellows, physician assistants, researchers, case managers, and other healthcare professionals interested in the treatment of cancer are also invited to attend.

Learning Objectives:

Upon completion of this activity, participants should be better prepared to:

  1. Determine the most appropriate testing strategies to stratify risk and inform clinical decision-making in the management of cancer
  2. Describe important clinical trial results that inform treatment practices and are altering care paradigms for patients with hematologic malignancies and solid tumors
  3. Identify immunotherapeutic, chemotherapeutic, and targeted approaches demonstrated by recent evidence to optimize clinical outcomes
  4. Delineate methods multidisciplinary teams can proactively apply to prevent and mitigate the impact of treatment-related toxicities findings in the context of evolving treatment pathways to improve care for patients with cancer
  5. Assess practice-changing evidence and apply these findings in the context of evolving treatment paradigms to optimize the care of patients with cancer

Program Co-Chairs

Adam M. Brufsky, MD, PhD
Professor of Medicine
Associate Chief, Division of Hematology/ Oncology
Co-Director, Comprehensive Breast Cancer Center Associate
Director, Clinical Investigation
University of Pittsburgh
Pittsburgh, PA

Benjamin Levy, MD
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC
 

William Oh, MD
Chief, Division of Hematology and Medical Oncology
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
Associate Director of Clinical Research
The Tisch Cancer Institute
New York, NY







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
31
Filter By